Oestrogen replacement in postmenopausal women

Age and Ageing

Volumn 44, Issue 4, 2015, Pages 551-558

  Sassarini, Jenifer ^a   Lumsden, Mary Ann ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Menopause; Oestrogen replacement therapy; Older people

Indexed keywords

ALPHA TOCOPHEROL; BISPHOSPHONIC ACID DERIVATIVE; CIMICIFUGA RACEMOSA EXTRACT; CONJUGATED ESTROGEN; DENOSUMAB; DESVENLAFAXINE; ESTRADIOL; ESTROGEN; FLUOXETINE; GABAPENTIN; LUBRICATING AGENT; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; OSPEMIFENE; PARATHYROID HORMONE; PAROXETINE; PHYTOESTROGEN; PLACEBO; PRIMROSE OIL; PROGESTERONE; RALOXIFENE; STRONTIUM RANELATE; VENLAFAXINE;

ACUPUNCTURE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CREAM; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESTROGEN THERAPY; EXERCISE; FEMALE SEXUAL DYSFUNCTION; HOT FLUSH; HUMAN; LIVER TOXICITY; MEMORY DISORDER; MENOPAUSAL SYNDROME; MOOD DISORDER; NIGHT SWEAT; NONHUMAN; OBESITY; OVERACTIVE BLADDER; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; TABLET; UNSPECIFIED SIDE EFFECT; VAGINA ATROPHY; VAGINA DISEASE; VAGINA PESSARY; VAGINA RING; VAGINAL DRYNESS; VASOMOTOR DISORDER; VULVA DISEASE; AGING; DRUG EFFECTS; FEMALE; HOT FLASHES; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PROCEDURES;

AGING; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 84937413247     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afv069     Document Type: Article

References (78)

1. NIo Health. National Institutes of Health State-of-the-Science Conference Statement: management of menopause-related symptoms. Ann Intern Med 2005; 142(12 Pt 1): 1003-13.
2. Gold EB, Bromberger J, Crawford S et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001; 153: 865-74.
3. Hale GE, Burger HG. Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause. Best Pract Res Clin Obstet Gynaecol 2009; 23: 7-23.
4. Soules MR, Sherman S, Parrott E. Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med 2001; 10: 843-8.
5. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994; 29: 319-36.
6. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999; 180: 312-6.
7. Taylor M. Psychological consequences of surgical menopause. J Reprod Med 2001; 46(Suppl 3): 317-24.
8. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; 18.
9. Rossouw JE, Anderson GL, Prentice R, LaCroix AZ, Kooperberg C, Stefanick ML. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized control trial. JAMA 2002; 288: 321-33.
10. Lagro-Janssen A, Knufing MW, Schreurs L, van Weel C. Significant fall in hormone replacement therapy prescription in general practice. Fam Pract 2010; 27: 424-9.
11. Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310: 1353-68.
12. de Villiers TJ, Gass MLS, Haines CJ et al. Global Consensus Statement on menopausal hormone therapy. Climacteric 2013; 16: 203-4.
13. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291: 1610-20.
14. Nordin BEC, Jones MM, Crilly RG, Marshail DH, Brooke R. A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women. Maturitas 1980; 2: 247-51.
15. Prior JC, Nielson JD, Hitchcock CL, Williams LA, Vigna YM, Dean CB. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci 2007; 112: 517-25.
16. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999; 94: 225-8.
17. Benster B, Carey A, Wadsworth F, Vashisht A, Domoney C, Studd J. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int 2009; 15: 63-9.
18. Landgren MB, Coelingh Bennink HJT, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002; 109: 1109-14.
19. Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. BJOG 1998; 105: 904-11.
20. Kenemans P, Bundred NJ, Foidart J-M et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135-46.
21. Stearns V, Slack R, Greep N et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23: 6919-30.
22. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289: 2827-34.
23. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059-63.
24. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105: 161-6.
25. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes 10.1200/ JCO.20.6.1578. J Clin Oncol 2002; 20: 1578-83.
26. Suvanto-Luukkonen E, Koivunen R, Sundstrom H et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebocontrolled, double-blind study. Menopause 2005; 12: 18-26.
27. Speroff L, Gass M, Constantine GD, Olivier S; Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111: 77-87.
28. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009; 200: 172e1-172e10.
29. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009; 70: 1688-97.
30. Nelson HD, Vesco KK, Haney E et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295: 2057-71.
31. Reddy SY, Warner H, Guttuso T Jr et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108: 41-8.
32. Barton DL, Loprinzi CL, Quella SK et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16: 495-500.
33. Wong VC, Lim CE, Luo X, Wong WS. Current alternative and complementary therapies used in menopause. Gynecol Endocrinol 2009; 25: 166-74.
34. Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009; 16: 72-84.
35. Lee MS, Shin B-C, Ernst E. Acupuncture for treating menopausal hot flushes: a systematic review. Climacteric 2009; 12: 16-25.
36. Daley A, Stokes-Lampard H, Mutrie N, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014; 11: CD006108.
37. Chenoy R, Hussain S, Tayob Y, O'Brien PMS, Moss MY, Morse PF. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ 1994; 308: 501-3.
38. Smith AL. Estrogen replacement therapy for the treatment of postmenopausal genitourinary tract dysfunction. Discov Med 2010; 10: 500-10.
39. McCall-Hosenfeld JS, Jaramillo SA, Legault C et al. Correlates of sexual satisfaction among sexually active postmenopausal women in the Women's Health Initiative-Observational Study. J Gen Intern Med 2008; 23: 2000-9.
40. Schneidewind-Skibbe A, Hayes RD, Koochaki PE, Meyer J, Dennerstein L. The frequency of sexual intercourse reported by women: a review of community-based studies and factors limiting their conclusions. J Sex Med 2008; 5: 301-35.
41. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA)-results from an international survey. Climacteric 2012; 15: 36-44.
42. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006: CD001500.
43. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010; 13: 509-22.
44. Bachmann GA, Leiblum SR, Kemmann E, Colburn DW, Swartzman L, Shelden R. Sexual expression and its determinants in the post-menopausal woman. Maturitas 1984; 6: 19-29.
45. Suckling JA et al. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; 4.
46. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009; 12: 91-105.
47. Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181-94.
48. Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 2012; 135: 603-9.
49. Wills S, Ravipati A, Venuturumilli P et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012; 8: 144-8.
50. Biglia N, Peano E, Sgandurra P et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010; 26: 404-12.
51. Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20: 623-30.
52. Bachmann GA, Komi JO, Ospemifene Study G. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17: 480-6.
53. Coyne KS, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003; 92: 731-5.
54. Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand 1984; 63: 257-60.
55. Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CMA. Oestrogen therapy for urinary incontinence in postmenopausal women. Cochrane Database Syst Rev 2012; 10: CD001405.
56. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97: 116-20.
57. Abrams P, Andersson KE, Birder L et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010; 29: 213-40.
58. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009; 11: 229.
59. Compston J, Bowring C, Cooper A et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013; 75: 392-6.
60. Writing group on osteoporosis for the British Menopause Society Council: Farook Al-Azzawi DB, Tim Hillard, Margaret Rees, John Studd, Jenny Williamson. Prevention and Treatment of osteoporosis in women. BMS Consensus Statements, 2015. http://www.thebms.org.uk/statementcontent.php?id=6 (26 April 2015, date last accessed).
61. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.
62. Sullivan JM, Vander Zwaag R, Hughes JP et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopasual women. Arch Intern Med 1990; 150: 2557-62.
63. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
64. Prentice RL, Manson JE, Langer RD et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009; 170: 12-23.
65. Schierbeck LL, Rejnmark L, Landbo Tofteng C et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409.
66. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308: 1583-7.
67. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
68. Kernohan AF, Spiers A, Sattar N et al. Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes. Diab Vasc Dis Res 2004; 1: 82-8.
69. Manson JE, Rimm EB, Colditz GA et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 1992; 2: 665-73.
70. Walf AA, Frye CA. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology 2006; 31: 1097-111.
71. Osterlund MK. Underlying mechanisms mediating the antidepressant effects of estrogens. Biochim Biophys Acta 2010; 1800: 1136-44.
72. Henderson VW. Action of estrogens in the aging brain: dementia and cognitive aging. Biochim Biophys Acta 2010; 1800: 1077-83.
73. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA; Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002; 287: 591-7.
74. Schmidt PJ. Mood, depression, and reproductive hormones in the menopausal transition. Am J Med 2005; 118 Suppl 12B: 54-8.
75. Rachon D, Teede H. Ovarian function and obesity-interrelationship, impact on women's reproductive lifespan and treatment options. Mol Cell Endocrinol 2010; 316: 172-9.
76. Thurston RC. The skinny on body fat and vasomotor symptoms. Menopausal Med 2009; 17: s1-6.
77. Kudish BI, Iglesia CB, Sokol RJ et al. Effect of weight change on natural history of pelvic organ prolapse. Obstet Gynecol 2009; 113: 81-8.
78. Thurston RC, Sowers MR, Chang Yet al. Adiposity and reporting of vasomotor symptoms among midlife women: the study of Women's Health Across the Nation. Am J Epidemiol 2008; 167: 78-85.